

Global Cell Line Development CDMO Market 2026 by Company, Regions, Type and Application, Forecast to 2032

<https://marketpublishers.com/r/G92B1287F71FEN.html>

Date: June 2026

Pages: 166

Price: US\$ 3,480.00 (Single User License)

ID: G92B1287F71FEN

Abstracts

According to our (Global Info Research) latest study, the global Cell Line Development CDMO market size was valued at US\$ 1723 million in 2025 and is forecast to a readjusted size of US\$ 2597 million by 2032 with a CAGR of 6.0% during review period.

Cell Line Development (CDMO) refers to a contract research and manufacturing organization that provides biopharmaceutical companies with end-to-end outsourcing services from gene sequencing to stable production cell lines. Its core tasks include: transfecting target genes (such as antibody or recombinant protein genes) into host cells (usually CHO or HEK293); obtaining highly expressed, genetically stable monoclonal cell lines through clonal screening, pressurized amplification, and single-cell isolation; subsequently, characterizing the cell lines (including yield, product quality, genetic stability, and viral safety testing); and establishing master cell banks and working cell banks that comply with Good Manufacturing Practices (GMP). This service aims to shorten the biopharmaceutical development cycle, reduce upfront infrastructure investment, ensure cell line compliance and process scalability, and is a crucial starting point for the development of antibody, gene therapy, and recombinant protein drugs.

The global Cell Line Development CDMO market is dominated by a three-way split between North America, Europe, and Asia. North America leads in monoclonal antibody and gene therapy vector cell line development, with companies like Catalent and Thermo Fisher dominating the high-end market thanks to their mature platforms; however, overcapacity and price competition are emerging. Europe, with companies like Lonza and Sartorius possessing significant advantages in complex proteins and regulatory compliance, supports the demand from small and medium-sized biotechnology companies; however, energy costs and talent shortages constrain its

expansion speed. China, relying on companies like WuXi Biologics and Genscript, is rapidly developing, leveraging cost advantages and a large biosimilar pipeline to seize market share. It is penetrating from cell line engineering into high-end complex proteins and viral vectors, but intellectual property risks and regulatory approvals in Europe and the US remain obstacles to overseas expansion. Japan has solid technology in stable cell line development, but its expansion is limited due to the slow growth of its domestic biopharmaceutical market. Future trends include: AI-based clone screening and automated cell line engineering to shorten development cycles, site-specific integration technologies to improve yield uniformity, and the extension and integration of cell culture CDMOs towards upstream technologies. Key obstacles include: lengthy development cycles due to compliance requirements, reliance on imported key raw materials (such as serum-free culture media and transfection reagents), and increased regulatory complexity associated with global multi-center filings. Dynamically, leading CDMOs are balancing costs and global supply networks through mergers and acquisitions and partnerships with Chinese/Indian companies to establish factories.

This report is a detailed and comprehensive analysis for global Cell Line Development CDMO market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.

Key Features:

Global Cell Line Development CDMO market size and forecasts, in consumption value (\$ Million), 2021-2032

Global Cell Line Development CDMO market size and forecasts by region and country, in consumption value (\$ Million), 2021-2032

Global Cell Line Development CDMO market size and forecasts, by Type and by Application, in consumption value (\$ Million), 2021-2032

Global Cell Line Development CDMO market shares of main players, in revenue (\$ Million), 2021-2026

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Cell Line Development CDMO

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Cell Line Development CDMO market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Lonza, Samsung Biologics, AGC Biologics, ProBio CDMO, Creative Biolabs, ProBioGen, InvivoGen, Eurofins Discovery, Innoprot, AcceGen, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market segmentation

Cell Line Development CDMO market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type

CHO Cell Line

HEK293 Cell Line

Others

Market segment by Technology

Glutamine Synthase (GS) System

Dihydrofolate Reductase (DHFR) System

Site-Directed Integration System

Transient Expression System

Others

Market segment by Expression

Low Expression (

Contents

1 MARKET OVERVIEW

1.1 Product Overview and Scope

1.2 Market Estimation Caveats and Base Year

1.3 Classification of Cell Line Development CDMO by Type

1.3.1 Overview: Global Cell Line Development CDMO Market Size by Type: 2021 Versus 2025 Versus 2032

1.3.2 Global Cell Line Development CDMO Consumption Value Market Share by Type in 2025

1.3.3 CHO Cell Line

1.3.4 HEK293 Cell Line

1.3.5 Others

1.4 Classification of Cell Line Development CDMO by Technology

1.4.1 Overview: Global Cell Line Development CDMO Market Size by Technology: 2021 Versus 2025 Versus 2032

1.4.2 Global Cell Line Development CDMO Consumption Value Market Share by Technology in 2025

1.4.3 Glutamine Synthase (GS) System

1.4.4 Dihydrofolate Reductase (DHFR) System

1.4.5 Site-Directed Integration System

1.4.6 Transient Expression System

1.4.7 Others

1.5 Classification of Cell Line Development CDMO by Expression

1.5.1 Overview: Global Cell Line Development CDMO Market Size by Expression: 2021 Versus 2025 Versus 2032

1.5.2 Global Cell Line Development CDMO Consumption Value Market Share by Expression in 2025

1.5.3 Low Expression (

List Of Tables

LIST OF TABLES

Table 1. Global Cell Line Development CDMO Consumption Value by Type, (USD Million), 2021 & 2025 & 2032

Table 2. Global Cell Line Development CDMO Consumption Value by Technology, (USD Million), 2021 & 2025 & 2032

Table 3. Global Cell Line Development CDMO Consumption Value by Expression, (USD Million), 2021 & 2025 & 2032

Table 4. Global Cell Line Development CDMO Consumption Value by Application, (USD Million), 2021 & 2025 & 2032

Table 5. Global Cell Line Development CDMO Consumption Value by Region (2021-2026) & (USD Million)

Table 6. Global Cell Line Development CDMO Consumption Value by Region (2027-2032) & (USD Million)

Table 7. Lonza Company Information, Head Office, and Major Competitors

Table 8. Lonza Major Business

Table 9. Lonza Cell Line Development CDMO Product and Solutions

Table 10. Lonza Cell Line Development CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 11. Lonza Recent Developments and Future Plans

Table 12. Samsung Biologics Company Information, Head Office, and Major Competitors

Table 13. Samsung Biologics Major Business

Table 14. Samsung Biologics Cell Line Development CDMO Product and Solutions

Table 15. Samsung Biologics Cell Line Development CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 16. Samsung Biologics Recent Developments and Future Plans

Table 17. AGC Biologics Company Information, Head Office, and Major Competitors

Table 18. AGC Biologics Major Business

Table 19. AGC Biologics Cell Line Development CDMO Product and Solutions

Table 20. AGC Biologics Cell Line Development CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 21. ProBio CDMO Company Information, Head Office, and Major Competitors

Table 22. ProBio CDMO Major Business

Table 23. ProBio CDMO Cell Line Development CDMO Product and Solutions

Table 24. ProBio CDMO Cell Line Development CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026)

- Table 25. ProBio CDMO Recent Developments and Future Plans
- Table 26. Creative Biolabs Company Information, Head Office, and Major Competitors
- Table 27. Creative Biolabs Major Business
- Table 28. Creative Biolabs Cell Line Development CDMO Product and Solutions
- Table 29. Creative Biolabs Cell Line Development CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026)
- Table 30. Creative Biolabs Recent Developments and Future Plans
- Table 31. ProBioGen Company Information, Head Office, and Major Competitors
- Table 32. ProBioGen Major Business
- Table 33. ProBioGen Cell Line Development CDMO Product and Solutions
- Table 34. ProBioGen Cell Line Development CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026)
- Table 35. ProBioGen Recent Developments and Future Plans
- Table 36. InvivoGen Company Information, Head Office, and Major Competitors
- Table 37. InvivoGen Major Business
- Table 38. InvivoGen Cell Line Development CDMO Product and Solutions
- Table 39. InvivoGen Cell Line Development CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026)
- Table 40. InvivoGen Recent Developments and Future Plans
- Table 41. Eurofins Discovery Company Information, Head Office, and Major Competitors
- Table 42. Eurofins Discovery Major Business
- Table 43. Eurofins Discovery Cell Line Development CDMO Product and Solutions
- Table 44. Eurofins Discovery Cell Line Development CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026)
- Table 45. Eurofins Discovery Recent Developments and Future Plans
- Table 46. Innoprot Company Information, Head Office, and Major Competitors
- Table 47. Innoprot Major Business
- Table 48. Innoprot Cell Line Development CDMO Product and Solutions
- Table 49. Innoprot Cell Line Development CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026)
- Table 50. Innoprot Recent Developments and Future Plans
- Table 51. AcceGen Company Information, Head Office, and Major Competitors
- Table 52. AcceGen Major Business
- Table 53. AcceGen Cell Line Development CDMO Product and Solutions
- Table 54. AcceGen Cell Line Development CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026)
- Table 55. AcceGen Recent Developments and Future Plans
- Table 56. WuXi Biologics Company Information, Head Office, and Major Competitors

- Table 57. WuXi Biologics Major Business
- Table 58. WuXi Biologics Cell Line Development CDMO Product and Solutions
- Table 59. WuXi Biologics Cell Line Development CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026)
- Table 60. WuXi Biologics Recent Developments and Future Plans
- Table 61. GenScript Company Information, Head Office, and Major Competitors
- Table 62. GenScript Major Business
- Table 63. GenScript Cell Line Development CDMO Product and Solutions
- Table 64. GenScript Cell Line Development CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026)
- Table 65. GenScript Recent Developments and Future Plans
- Table 66. Pharmaron Company Information, Head Office, and Major Competitors
- Table 67. Pharmaron Major Business
- Table 68. Pharmaron Cell Line Development CDMO Product and Solutions
- Table 69. Pharmaron Cell Line Development CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026)
- Table 70. Pharmaron Recent Developments and Future Plans
- Table 71. Bio-Inno Company Information, Head Office, and Major Competitors
- Table 72. Bio-Inno Major Business
- Table 73. Bio-Inno Cell Line Development CDMO Product and Solutions
- Table 74. Bio-Inno Cell Line Development CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026)
- Table 75. Bio-Inno Recent Developments and Future Plans
- Table 76. Dingkang Biotech Company Information, Head Office, and Major Competitors
- Table 77. Dingkang Biotech Major Business
- Table 78. Dingkang Biotech Cell Line Development CDMO Product and Solutions
- Table 79. Dingkang Biotech Cell Line Development CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026)
- Table 80. Dingkang Biotech Recent Developments and Future Plans
- Table 81. FUJIFILM Company Information, Head Office, and Major Competitors
- Table 82. FUJIFILM Major Business
- Table 83. FUJIFILM Cell Line Development CDMO Product and Solutions
- Table 84. FUJIFILM Cell Line Development CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026)
- Table 85. FUJIFILM Recent Developments and Future Plans
- Table 86. JCR Pharmaceuticals Company Information, Head Office, and Major Competitors
- Table 87. JCR Pharmaceuticals Major Business
- Table 88. JCR Pharmaceuticals Cell Line Development CDMO Product and Solutions

- Table 89. JCR Pharmaceuticals Cell Line Development CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026)
- Table 90. JCR Pharmaceuticals Recent Developments and Future Plans
- Table 91. Sartorius Company Information, Head Office, and Major Competitors
- Table 92. Sartorius Major Business
- Table 93. Sartorius Cell Line Development CDMO Product and Solutions
- Table 94. Sartorius Cell Line Development CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026)
- Table 95. Sartorius Recent Developments and Future Plans
- Table 96. Oxford BioMedica Company Information, Head Office, and Major Competitors
- Table 97. Oxford BioMedica Major Business
- Table 98. Oxford BioMedica Cell Line Development CDMO Product and Solutions
- Table 99. Oxford BioMedica Cell Line Development CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026)
- Table 100. Oxford BioMedica Recent Developments and Future Plans
- Table 101. Cobra Biologics Company Information, Head Office, and Major Competitors
- Table 102. Cobra Biologics Major Business
- Table 103. Cobra Biologics Cell Line Development CDMO Product and Solutions
- Table 104. Cobra Biologics Cell Line Development CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026)
- Table 105. Cobra Biologics Recent Developments and Future Plans
- Table 106. Evotec Company Information, Head Office, and Major Competitors
- Table 107. Evotec Major Business
- Table 108. Evotec Cell Line Development CDMO Product and Solutions
- Table 109. Evotec Cell Line Development CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026)
- Table 110. Evotec Recent Developments and Future Plans
- Table 111. Catalent Company Information, Head Office, and Major Competitors
- Table 112. Catalent Major Business
- Table 113. Catalent Cell Line Development CDMO Product and Solutions
- Table 114. Catalent Cell Line Development CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026)
- Table 115. Catalent Recent Developments and Future Plans
- Table 116. Thermo Fisher Scientific Company Information, Head Office, and Major Competitors
- Table 117. Thermo Fisher Scientific Major Business
- Table 118. Thermo Fisher Scientific Cell Line Development CDMO Product and Solutions
- Table 119. Thermo Fisher Scientific Cell Line Development CDMO Revenue (USD

- Million), Gross Margin and Market Share (2021-2026)
- Table 120. Thermo Fisher Scientific Recent Developments and Future Plans
- Table 121. Cytiva Company Information, Head Office, and Major Competitors
- Table 122. Cytiva Major Business
- Table 123. Cytiva Cell Line Development CDMO Product and Solutions
- Table 124. Cytiva Cell Line Development CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026)
- Table 125. Cytiva Recent Developments and Future Plans
- Table 126. Charles River Laboratories Company Information, Head Office, and Major Competitors
- Table 127. Charles River Laboratories Major Business
- Table 128. Charles River Laboratories Cell Line Development CDMO Product and Solutions
- Table 129. Charles River Laboratories Cell Line Development CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026)
- Table 130. Charles River Laboratories Recent Developments and Future Plans
- Table 131. Abzena Company Information, Head Office, and Major Competitors
- Table 132. Abzena Major Business
- Table 133. Abzena Cell Line Development CDMO Product and Solutions
- Table 134. Abzena Cell Line Development CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026)
- Table 135. Abzena Recent Developments and Future Plans
- Table 136. Shilpa Biologicals Company Information, Head Office, and Major Competitors
- Table 137. Shilpa Biologicals Major Business
- Table 138. Shilpa Biologicals Cell Line Development CDMO Product and Solutions
- Table 139. Shilpa Biologicals Cell Line Development CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026)
- Table 140. Shilpa Biologicals Recent Developments and Future Plans
- Table 141. Teijin Company Information, Head Office, and Major Competitors
- Table 142. Teijin Major Business
- Table 143. Teijin Cell Line Development CDMO Product and Solutions
- Table 144. Teijin Cell Line Development CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026)
- Table 145. Teijin Recent Developments and Future Plans
- Table 146. Global Cell Line Development CDMO Revenue (USD Million) by Players (2021-2026)
- Table 147. Global Cell Line Development CDMO Revenue Share by Players (2021-2026)

Table 148. Breakdown of Cell Line Development CDMO by Company Type (Tier 1, Tier 2, and Tier 3)

Table 149. Market Position of Players in Cell Line Development CDMO, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025

Table 150. Head Office of Key Cell Line Development CDMO Players

Table 151. Cell Line Development CDMO Market: Company Product Type Footprint

Table 152. Cell Line Development CDMO Market: Company Product Application Footprint

Table 153. Cell Line Development CDMO New Market Entrants and Barriers to Market Entry

Table 154. Cell Line Development CDMO Mergers, Acquisition, Agreements, and Collaborations

Table 155. Global Cell Line Development CDMO Consumption Value (USD Million) by Type (2021-2026)

Table 156. Global Cell Line Development CDMO Consumption Value Share by Type (2021-2026)

Table 157. Global Cell Line Development CDMO Consumption Value Forecast by Type (2027-2032)

Table 158. Global Cell Line Development CDMO Consumption Value by Application (2021-2026)

Table 159. Global Cell Line Development CDMO Consumption Value Forecast by Application (2027-2032)

Table 160. North America Cell Line Development CDMO Consumption Value by Type (2021-2026) & (USD Million)

Table 161. North America Cell Line Development CDMO Consumption Value by Type (2027-2032) & (USD Million)

Table 162. North America Cell Line Development CDMO Consumption Value by Application (2021-2026) & (USD Million)

Table 163. North America Cell Line Development CDMO Consumption Value by Application (2027-2032) & (USD Million)

Table 164. North America Cell Line Development CDMO Consumption Value by Country (2021-2026) & (USD Million)

Table 165. North America Cell Line Development CDMO Consumption Value by Country (2027-2032) & (USD Million)

Table 166. Europe Cell Line Development CDMO Consumption Value by Type (2021-2026) & (USD Million)

Table 167. Europe Cell Line Development CDMO Consumption Value by Type (2027-2032) & (USD Million)

Table 168. Europe Cell Line Development CDMO Consumption Value by Application

(2021-2026) & (USD Million)

Table 169. Europe Cell Line Development CDMO Consumption Value by Application (2027-2032) & (USD Million)

Table 170. Europe Cell Line Development CDMO Consumption Value by Country (2021-2026) & (USD Million)

Table 171. Europe Cell Line Development CDMO Consumption Value by Country (2027-2032) & (USD Million)

Table 172. Asia-Pacific Cell Line Development CDMO Consumption Value by Type (2021-2026) & (USD Million)

Table 173. Asia-Pacific Cell Line Development CDMO Consumption Value by Type (2027-2032) & (USD Million)

Table 174. Asia-Pacific Cell Line Development CDMO Consumption Value by Application (2021-2026) & (USD Million)

Table 175. Asia-Pacific Cell Line Development CDMO Consumption Value by Application (2027-2032) & (USD Million)

Table 176. Asia-Pacific Cell Line Development CDMO Consumption Value by Region (2021-2026) & (USD Million)

Table 177. Asia-Pacific Cell Line Development CDMO Consumption Value by Region (2027-2032) & (USD Million)

Table 178. South America Cell Line Development CDMO Consumption Value by Type (2021-2026) & (USD Million)

Table 179. South America Cell Line Development CDMO Consumption Value by Type (2027-2032) & (USD Million)

Table 180. South America Cell Line Development CDMO Consumption Value by Application (2021-2026) & (USD Million)

Table 181. South America Cell Line Development CDMO Consumption Value by Application (2027-2032) & (USD Million)

Table 182. South America Cell Line Development CDMO Consumption Value by Country (2021-2026) & (USD Million)

Table 183. South America Cell Line Development CDMO Consumption Value by Country (2027-2032) & (USD Million)

Table 184. Middle East & Africa Cell Line Development CDMO Consumption Value by Type (2021-2026) & (USD Million)

Table 185. Middle East & Africa Cell Line Development CDMO Consumption Value by Type (2027-2032) & (USD Million)

Table 186. Middle East & Africa Cell Line Development CDMO Consumption Value by Application (2021-2026) & (USD Million)

Table 187. Middle East & Africa Cell Line Development CDMO Consumption Value by Application (2027-2032) & (USD Million)

Table 188. Middle East & Africa Cell Line Development CDMO Consumption Value by Country (2021-2026) & (USD Million)

Table 189. Middle East & Africa Cell Line Development CDMO Consumption Value by Country (2027-2032) & (USD Million)

Table 190. Global Key Players of Cell Line Development CDMO Upstream (Raw Materials)

Table 191. Global Cell Line Development CDMO Typical Customers

List Of Figures

LIST OF FIGURES

Figure 1. Cell Line Development CDMO Picture

Figure 2. Global Cell Line Development CDMO Consumption Value by Type, (USD Million), 2021 & 2025 & 2032

Figure 3. Global Cell Line Development CDMO Consumption Value Market Share by Type in 2025

Figure 4. CHO Cell Line

Figure 5. HEK293 Cell Line

Figure 6. Others

Figure 7. Global Cell Line Development CDMO Consumption Value by Technology, (USD Million), 2021 & 2025 & 2032

Figure 8. Global Cell Line Development CDMO Consumption Value Market Share by Technology in 2025

Figure 9. Glutamine Synthase (GS) System

Figure 10. Dihydrofolate Reductase (DHFR) System

Figure 11. Site-Directed Integration System

Figure 12. Transient Expression System

Figure 13. Others

Figure 14. Global Cell Line Development CDMO Consumption Value by Expression, (USD Million), 2021 & 2025 & 2032

Figure 15. Global Cell Line Development CDMO Consumption Value Market Share by Expression in 2025

Figure 16. Low Expression (

I would like to order

Product name: Global Cell Line Development CDMO Market 2026 by Company, Regions, Type and Application, Forecast to 2032

Product link: <https://marketpublishers.com/r/G92B1287F71FEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G92B1287F71FEN.html>